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ABSTRACT
The epithelial-mesenchymal transition (EMT) endows carcinoma cells with 
phenotypic plasticity that can facilitate the formation of cancer stem cells (CSCs) 
and contribute to the metastatic cascade. While there is substantial support for the 
role of EMT in driving cancer cell dissemination, less is known about the intracellular 
molecular mechanisms that govern formation of CSCs via EMT. Here we show that 
β2 and β5 proteasome subunit activity is downregulated during EMT in immortalized 
human mammary epithelial cells. Moreover, selective proteasome inhibition enabled 
mammary epithelial cells to acquire certain morphologic and functional characteristics 
reminiscent of cancer stem cells, including CD44 expression, self-renewal, and tumor 
formation. Transcriptomic analyses suggested that proteasome-inhibited cells share 
gene expression signatures with cells that have undergone EMT, in part, through 
modulation of the TGF-β signaling pathway. These findings suggest that selective 
downregulation of proteasome activity in mammary epithelial cells can initiate the 
EMT program and acquisition of a cancer stem cell-like phenotype. As proteasome 
inhibitors become increasingly used in cancer treatment, our findings highlight a 
potential risk of these therapeutic strategies and suggest a possible mechanism by 
which carcinoma cells may escape from proteasome inhibitor-based therapy.
INTRODUCTION
Cancer is one of the leading causes of death in 
the United States, and up to 90% of cancer-associated 
mortality can be attributed to therapy-resistant 
metastatic disease [1]. During the metastatic cascade, 
tumor cells gain the capacity to invade locally and 
disseminate into the vasculature. However, not all cells 
that enter the vasculature go on to colonize distant sites. 
Only a small subset of invading tumor cells acquire 
characteristics of cancer stem cells (CSCs) needed to 
establish macrometastases, namely self-renewal capacity, 
proliferative potential, and chemoresistance [2]. There is 
increasing evidence to support the involvement of CSCs in 
multiple types of hematologic and solid tumors, including 
breast, brain, prostate, colon, liver, and pancreatic, among 
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others [3]. Although the ontogeny of CSCs is incompletely 
understood, a developmental process known as the 
epithelial-mesenchymal transition (EMT) has been shown 
to promote the development of cells with CSC properties 
[4-8]. Previous studies have identified the transcription 
factors TWIST1, SNAI1, and ZEB1 as key inducers of 
EMT, metastasis, and the CSC phenotype [3, 6, 8-10]. 
Thus, identifying the factors that regulate EMT is highly 
relevant to cancer therapy as these stimuli can be targeted 
to block metastasis, and potentially CSC formation, in 
carcinomas.
Recent evidence suggests that CSCs may exhibit 
decreased proteasome activity [11-15]. The 26S 
proteasome is comprised of a 20S core complex that 
contains β1, β2, and β5 catalytic subunits that contain 
caspase-like, trypsin-like, and chymotrypsin-like 
proteolytic sites, respectively [16, 17]. The observation 
of decreased proteasome activity in CSCs led us to 
hypothesize that downregulation of proteasome activity 
might be causally related to the acquisition of the CSC 
phenotype, via EMT.
Here we show that immortalized human mammary 
epithelial (HMLE) cells and MCF10A cells, both well-
established model systems for EMT [6], decrease their 
proteasome activity as they undergo EMT. Strikingly, 
we observed that selective inhibition of β2 or β5 subunit 
proteasome activity was sufficient to induce HMLE 
and MCF10A cells to acquire key morphologic and 
functional characteristics of the EMT. Transcriptomic 
analyses suggested that proteasome-inhibited cells share 
gene expression signatures with cells that had undergone 
EMT, in part, through modulation of the TGF-β signaling 
pathway. Taken together, these data suggest that 
downregulation of proteasome activity in breast cancer 
cells can initiate the EMT program, thereby conferring 
upon these cells key attributes of CSCs.
RESULTS
Downregulation of proteasome activity is 
associated with EMT
We first sought to determine whether cells 
undergoing EMT alter their levels of proteasome activity. 
We utilized HMLE cells in which EMT can be induced 
by stable overexpression of SNAI1 or TWIST1, or by 
treatment with TGF-β1 (hereafter referred to as HMLE-
Snail, HMLE-Twist, or HMLE+TGF-β1, respectively), 
as previously described [6, 18-22]. We determined 
proteasome activity by using subunit-specific probes 
that bind irreversibly to the β1, β2, or β5 proteasome 
catalytic subunits (Supplementary Figure S1) [23-
25]. We observed that cells that had undergone EMT 
exhibited a 25-30% reduction in β2 and β5, but not β1, 
subunit activity compared to cells that had not undergone 
EMT (Figure 1A, 1B). This is likely due to a reduction 
in specific proteasome activity, since total protein and 
mRNA expression of these subunits remained unaffected 
by EMT induction (Supplementary Figure S2A and 
S2B). In support of this finding, we observed that cells 
that had undergone EMT also exhibited an accumulation 
of ubiquitinated proteins, compared to their epithelial 
parental cells (Figure 1C). Taken together, these data 
suggest that HMLE cells decrease specific proteasome 
catalytic activities - not proteasome amounts - during 
EMT.
Selective inhibition of proteasome activity induces 
the EMT phenotype
To investigate whether the reduction in proteasome 
activity is mechanistically linked to the process of EMT, 
we treated HMLE cells with selective β1, β2, or β5 
proteasome subunit inhibitors (Supplementary Figure S1) 
[25-27]. We then assessed the cell surface expression of 
CD44 by HMLE cells after 14 days of treatment. High 
expression of CD44 has been associated with human 
breast cancer stem cells [28, 29] as well as with HMLE 
cells that have undergone EMT [6]. Strikingly, 98% of 
cells treated with β2 subunit inhibitor and 57% of those 
treated with β5 subunit inhibitor expressed high levels of 
CD44, compared to 12% of DMSO-treated cells (Figure 
2A). By contrast, cells treated with the β1 subunit inhibitor 
expressed low levels of CD44 (Figure 2A), consistent with 
the lack of change in β1 subunit proteasome activity within 
cells that had undergone EMT (Figure 1A, 1B). To exclude 
the possibility that the increase of the CD44high population 
was due to selective outgrowth of CD44high cells, HMLE 
cells were first FACS sort-purified for low expression of 
CD44, then treated with selective proteasome inhibitors 
(Supplementary Figure S3A). We found that CD44low cells 
treated with proteasome inhibitors gave rise to CD44high 
cells after 14 days of treatment (Supplementary Figure 
S3B), demonstrating that these cells arose directly from 
CD44low cells.
CD44high cells that emerged after treatment with 
selective β2 or β5 subunit inhibitors lost their cobblestone-
like appearance and acquired the fibroblast-like 
morphology characteristic of mesenchymal cells (Figure 
2B). Moreover, cells treated with selective proteasome 
inhibitors decreased their expression of epithelial 
marker E-cadherin and increased their expression of 
mesenchymal markers fibronectin and vimentin, as shown 
by immunofluorescence and immunoblot analyses (Figure 
2C, 2D). Together, these results suggest that selective β2 
or β5 subunit inhibition induces HMLE cells to acquire an 
EMT phenotype.
In addition to exhibiting mesenchymal 
characteristics, we found that cells with lower levels of 
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proteasome activity exhibited decreased apoptosis, in 
comparison to parental HMLE cells, when treated with 
the pan-proteasome inhibitor epoxomicin (Figure 2E). 
These results suggest that the reduced level of proteasome 
activity associated with EMT confers increased 
resistance to the cytotoxic effects of pan-proteasome 
inhibition. Furthermore, these results are consistent with 
prior observations that CSCs may be more resistant to 
proteasome inhibitors [14].
We found that a second non-tumorigenic 
human mammary epithelial cell line, MCF10A, also 
downregulated β2 and β5 subunit activity while 
undergoing EMT in response to TGF-β1 (Supplementary 
Figure S4A). MCF10A cells have been previously shown 
to decrease their expression of CD24 as they undergo 
EMT [7]. We observed a decrease in CD24 expression 
in MCF10A cells treated with selective β2 or β5 subunit 
inhibitors, suggesting that these cells had undergone 
EMT (Supplementary Figure S4B). In addition, MCF10A 
cells treated with β2 or β5 subunit inhibitors exhibited 
a fibroblast-like morphology, decreased expression 
of epithelial markers, and increased expression of 
mesenchymal markers at the protein and mRNA levels 
(Supplementary Figure S4C-F). Together, these results 
suggest that induction of the EMT phenotype as a result of 
selective β2 or β5 inhibition of proteasome activity may 
be a generalizable phenomenon.
Cells treated with selective proteasome inhibitors 
acquire the ability to self-renew
We next sought to confirm that the CD44high cells that 
had arisen following treatment with proteasome inhibitors 
Figure 1: Downregulation of proteasome activity is associated with EMT. A. β1, β2, and β5 subunit proteasome activity in 
HMLE, HMLE-Snail, HMLE-Twist, and HMLE+TGF-β1 were measured by in-gel proteasome activity assay. Representative images of 
the SDS-PAGE gels are shown. Vertical spaces inserted between lanes indicate removal of intervening, irrelevant samples. All the samples 
were run on the same gel and imaged in a single scan. B. Quantification of β1, β2, and β5 subunit activity as well as total catalytic activity 
(the sum of the three subunits) presented as percent change relative to HMLE. Error bars indicate standard error of the mean (SEM) (n ≥ 
3). C. Immunoblot of whole cell lysates from HMLE cells using an anti-ubiquitin antibody, representative of 3 independent experiments. 
β-actin served as a loading control. Vertical spaces inserted between lanes indicate removal of intervening, irrelevant samples. All the 
samples were run on the same gel, transferred and blotted together, and imaged in a single scan.
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Figure 2: Selective inhibition of proteasome activity induces an EMT phenotype. A. Flow cytometry analysis of CD44 
surface expression and side scatter (SSC) after 14 days of treatment with DMSO or β1, β2, or β5 subunit inhibitor. Percentage of CD44high 
cells within the live population is indicated. Representative result of three independent experiments is shown. B. Representative brightfield 
images of HMLE, HMLE+β2 inhibitor, HMLE+β5 inhibitor, and HMLE-Snail after 14 days of treatment. All the images were taken at 10X 
magnification. Schematic diagram depicts the change in cell morphology during EMT. C. Confocal microscopy of E-cadherin (left panel; 
green), fibronectin (right panel; green), or vimentin (red) in HMLE cells treated with β2 subunit inhibitor or β5 subunit inhibitor for 14 days. 
Images were taken at 40X magnification. D. Immunoblot of whole cell lysates from HMLE, HMLE+β2 inhibitor, HMLE+β5 inhibitor, 
or HMLE+TGF-β1 using anti-E-cadherin, anti-fibronectin, and anti-vimentin antibodies, representative of 3 independent experiments. 
β-actin served as a loading control. E. Flow cytometric analysis of 7-AAD and Annexin-V expression in HMLE, HMLE+β2 inhibitor, 
HMLE+β5 inhibitor, and HMLE-Snail with or without 1 day of epoxomicin treatment. Percentage of 7-AAD+/AnnexinV+ cells is indicated. 
Representative result of three independent experiments is shown.
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Figure 3: Selective inhibition of proteasome activity endows HMLE cells with self-renewal ability in vitro and tumor-
initiating capacity in vivo. A. Quantification of primary mammospheres per 1000 seeded cells formed by HMLE, HMLE+β2 inhibitor, 
or HMLE-Snail. Error bars indicate SEM (n ≥ 3). B. Serial passage of mammospheres. Quantification is presented in the bar graph as the 
number of mammospheres formed per 1000 seeded cells. Error bars indicate SEM (n 3). C. Flow cytometric analysis of CD44 expression 
by HMLER-Twist, β2 subunit inhibitor-treated or DMSO-treated HMLER cells. Percentage of CD44high cells within the live population is 
indicated. Representative result of three independent experiments is shown. D. Quantification of primary and secondary mammospheres 
formed by HMLER, HMLER+β2 inhibitor, or HMLER-Twist, presented in the bar graph as the number of mammospheres formed per 
1000 seeded cells. Error bars indicate SEM (n ≥ 3). E. Primary tumor formation in immunodeficient mice 2 months after injection with 
HMLER, HMLER+β2 inhibitor, or HMLER-Twist cells. Error bars indicate SEM (n = 12 mice per group). Representative images of the 
tumors are also shown. 
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had indeed undergone EMT. We focused our studies 
on β2 subunit inhibition due to its more pronounced 
effect (Figure 2A). It has been previously demonstrated 
that HMLE cells that have undergone EMT exhibit an 
increased ability to self-renew, a characteristic typically 
associated with mammary epithelial stem cells [6, 30, 
31]. We therefore tested the ability of HMLE cells treated 
with proteasome inhibitors to form mammospheres, a 
capability indicative of self-renewal activity. Indeed, 
β2 subunit inhibitor-treated HMLE cells acquired an 
enhanced capacity to form mammospheres compared to 
DMSO-treated cells, both in primary assays and during 
subsequent serial passages (Figure 3A, 3B). These results 
suggest that selective proteasome inhibition confers self-
renewal capabilities to HMLE cells.
Selective inhibition of proteasome activity endows 
HMLER cells with tumor-initiating capacity in 
vivo
We next wished to determine whether selective 
proteasome inhibition also endowed HMLE cells with 
the ability to initiate tumors, another property of CSCs. 
Accordingly, we used a tumor xenograft system in 
which HMLE cells constitutively expressing RAS-V12H 
oncogene and TWIST1 (HMLER-Twist) renders them 
tumorigenic when injected into immunodeficient mice 
[32]. Similar to the behavior of proteasome-inhibited 
HMLE cells described above, HMLER cells treated with 
β2 subunit inhibitor acquired a CD44high phenotype and the 
ability to form mammospheres (Figure 3C, 3D). To test the 
tumorigenic potential of these cells, we injected HMLER, 
HMLER-Twist, or β2 subunit inhibitor-treated HMLER 
cells into immunodeficient mice. 92% of mice injected 
with HMLER-Twist or β2 inhibitor-treated HMLER cells 
developed tumors with a mean size of 0.5 cm; in contrast, 
mice injected with DMSO-treated HMLER cells did not 
develop tumors (Figure 3E). Taken together, these results 
suggest that downregulation of proteasome activity in 
HMLER cells can induce EMT and confer self-renewal 
and tumor-initiating capabilities, which are hallmarks of 
CSCs.
Low proteasome subunit expression is associated 
with human breast cancer and decreased patient 
survival
To determine whether the link between reduced 
proteasome activity and tumorigenicity might apply 
to human patients with breast carcinoma, we analyzed 
publicly available gene expression data from the 
Oncomine Platform and The Cancer Genome Atlas. 
Intriguingly, we found that tumor samples from patients 
with invasive breast carcinoma exhibited significantly 
lower PSMB2 and PSMB5 proteasome subunit mRNA 
expression compared to samples derived from normal 
tissue (Figure 4A). Moreover, breast cancer patients 
with tumors exhibiting the lowest quartile of PSMB2 and 
PSMB5 combined mRNA expression showed reduced 
5-year survival compared to patients with tumors in the 
highest quartile (Figure 4B). Together, these data suggest 
that low proteasome subunit expression may be useful as 
an indicator of poor prognosis for breast cancer patients.
Figure 4: Low proteasome subunit expression is associated with breast tissue from patients with breast cancer and 
decreased patient survival. A. PSMB2 and PSMB5 gene expression box plots from normal and tumor samples from the Finak dataset 
[47]. P < 0.01 for both comparisons. B. Kaplan-Meier survival curves for breast cancer patients stratified by intra-tumor expression (“high” 
vs “low”) of PSMB2 and PSMB5 mRNA.
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Selective inhibition of proteasome activity induces 
an EMT transcriptional program
To investigate the molecular mechanisms underlying 
proteasome inhibitor-induced EMT, we performed gene 
expression microarray analysis of DMSO-treated HMLE 
cells, cells treated with either β2 or β5 subunit inhibitors, 
and cells expressing Snail. 1,338 and 1,278 genes were 
differentially expressed in β2 and β5 subunit inhibitor-
treated HMLE cells, respectively, compared to DMSO-
treated cells. Among these differentially expressed genes 
were a number of transcripts that have been previously 
reported to be associated with EMT (Figure 5A). 
These included a number of upregulated mesenchymal 
markers ID1, KLK7, LCN2, and CEACAM6 as well as 
downregulated epithelial markers FOXA2, MIR205, 
and COL4A2 [9]. Moreover, key genes were validated 
by qPCR and we found that β2 and β5 inhibitor-treated 
HMLE cells exhibited increased expression of the EMT-
associated transcription factors, SNAI1, ZEB1/2, and 
TWIST1, as well as decreased expression of epithelial 
markers CDH1, TJP1, and CLDN1 (Figure 5B). 
Gene set enrichment analysis (GSEA) revealed that 
transcripts upregulated or downregulated upon proteasome 
inhibitor treatment were significantly enriched within the 
set of genes upregulated or downregulated in HMLE-
Snail, respectively (Figure 5C). These observations were 
confirmed by additional GSEA using datasets derived 
from the Molecular Signatures Database (Supplementary 
Table 1). Lastly, we applied Ingenuity Pathway Analysis 
(IPA) to the transcripts that were differentially expressed 
between β2 or β5 subunit inhibitor-treated HMLE cells 
and DMSO-treated cells. This analysis identified cellular 
movement, cell death and survival, cell growth and 
proliferation, and EMT as some of the most significantly 
enriched molecular and cellular functions across all 
samples (Table 1 and Figure 5D). Taken together, these 
analyses provide molecular evidence that β2 or β5 subunit 
inhibition induces HMLE cells to undergo EMT.
Selective proteasome inhibitor induces an EMT 
transcriptional program by stabilizing the 
TGF-β1 signaling pathway
In addition to identifying a link between proteasome 
inhibition and the EMT pathway, IPA analysis also 
identified the TGF-β1 signaling pathway as a putative 
upstream regulator driving the observed transcriptional 
changes in proteasome-inhibited HMLE cells (Table 1 
and Figure 6A). TGF-β1 signals through tetrameric TGF-β 
receptors 1 (TGFR1) and 2 (TGFR2) complexes, which 
phosphorylate SMAD2 (pSMAD2). SMAD4 combines 
with pSMAD2 to form multimeric SMAD-complexes 
that translocate into the nucleus and regulate transcription 
[9]. We hypothesized that reduced proteasome activity 
might result in increased stability of TGFR2 leading to 
increased TGF-β1 signaling. In support of this hypothesis, 
we observed increased cell surface expression of TGFR2 
in HMLE cells treated with β2 subunit inhibitor (Figure 
6B). Moreover, we found that treatment with β2 subunit 
inhibitor increased SMAD2 phosphorylation (Figure 6C) 
and increased SMAD4 nuclear localization by 2-fold 
Table 1: IPA analysis of differentially expressed genes.  
Transcripts differentially expressed in β2 or β5 inhibitor-treated HMLE cells are enriched in molecular and 
cellular functions involved in EMT. 
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Figure 5: Selective inhibition of proteasome activity induces an EMT transcriptional program. A. Volcano plots depicting 
differentially expressed genes in HMLE cells treated with β2 or β5 subunit inhibitors compared to DMSO-treated cells after 10 days. 
X-axis represents the Array Studio estimate and the y-axis represents the -Log10(Raw P-value). Significant differentially expressed genes 
are highlighted in red (upregulated) or in blue (downregulated). Selected genes of interest are indicated. B. mRNA levels of epithelial 
and mesenchymal markers in sorted CD44high HMLE cells treated with β2 (black bars) or β5 inhibitor (grey bars). GAPDH was used 
as a reference gene. Data are shown as fold change relative to DMSO-treated HMLE. Error bars indicate SEM (n ≥ 3). C. GSEA plots. 
Enrichment score is visualized in green. ES, enrichment score. FDR, false discovery rate. D. Heatmaps depicting Log2 fold change of 
differentially expressed genes in the EMT pathway in HMLE cells treated with β2 or β5 subunit inhibitors compared to DMSO-treated 
cells. Gene list was generated with IPA.
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(Figure 6D), compared to DMSO-treated cells. In line 
with these results, we also observed increased mRNA 
expression of SMAD target genes SNAI1, ZEB1/2, MMP2, 
and MMP9, as well as decreased expression of SMAD7, a 
negative regulator of TGF-β1 signaling (Figure 5B). 
To confirm that EMT induction in proteasome 
inhibitor-treated HMLE cells is due to TGF-β1 signaling, 
we repeated inhibitor treatment in the presence of an 
anti-TGF-β1 neutralizing antibody. We first validated the 
specificity of the neutralizing antibody in our system by 
showing that SMAD2 phosphorylation is blocked when 
HMLE cells are treated with TGF-β1 or proteasome 
inhibitors in the presence of the neutralizing antibody 
(Supplementary Figure S5A-B). Strikingly, we found that 
neutralizing anti-TGF-β1 antibodies prevented the β2 
subunit inhibitor-induced increase in CD44 cell surface 
expression (Figure 7A). Moreover, EMT-associated 
downregulation of E-cadherin and upregulation of 
fibronectin and vimentin, both at the protein and mRNA 
level, were prevented by anti-TGF-β1 antibody treatment 
(Figure 7B-7D). Taken together, these data suggest that a 
consequence of decreased β2 subunit proteasome activity 
Figure 6: Downregulation of proteasome activity enhances TGF-β1 signaling. A. Heatmaps depicting Log2 fold change 
of differentially expressed genes in the TGF-β1 signaling pathway in HMLE cells treated with β2 or β5 subunit inhibitors compared to 
DMSO-treated cells. B. Flow cytometric analysis of surface TGFR2 expression and SSC by HMLE cells treated for 1 day with DMSO 
or β2 subunit inhibitor. Percentage of TGFR2+ cells within the live population is indicated. Representative result of three independent 
experiments is shown. C. Immunoblot using anti-Phospho Smad2 (Ser465/467) antibody on whole cell lysates from DMSO- or beta2 
inhibitor-treated HMLE cells for 24 hours representative of 3 independent experiments. β-actin served as a loading control. Vertical spaces 
inserted between lanes indicate removal of intervening, irrelevant samples. All the samples were ran on the same gel, transferred and blotted 
together, and imaged in a single scan. D. Confocal microscopy of Smad4 (green) and DNA (blue; stained with DAPI) in HMLE cells treated 
with β2 subunit inhibitor for 3 hours. Images were taken at 40X magnification. Bar graph presents fold change in nuclear/cytoplasmic ratio 
relative to control treatment. Error bars indicate SEM (n ≥ 3).
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Figure 7: Proteasome inhibitor-induced EMT is dependent on TGF-β1 signaling. A. Flow cytometric analysis of CD44 
expression after 14 days of treatment with DMSO or β2 inhibitor, with or without neutralizing anti-TGF-β1 antibody. Percentage of CD44high 
cells within the live population is indicated. Representative result of three independent experiments is shown. B. Confocal microscopy of 
E-cadherin (left panel; green), fibronectin (right panel; green), or vimentin (red) in HMLE cells, HMLE cells+β2 subunit inhibitor, or 
HMLE cells+β2 subunit inhibitor with anti-TGF-β1 antibody for 14 days. Images were taken at 40X magnification. C. Immunoblot of 
whole cell lysates from HMLE, HMLE+β2 inhibitor, or HMLE cells+β2 subunit inhibitor treated with anti-TGF-β1 antibody, using anti-
E-cadherin, anti-fibronectin, and anti-vimentin antibodies. Images are representative of 3 independent experiments. β-Actin served as a 
loading control. Vertical spaces inserted between lanes indicate removal of intervening, irrelevant samples. All the samples were ran on the 
same gel, transferred and blotted together, and imaged in a single scan. D. mRNA levels of epithelial (CDH1) and mesenchymal markers 
(CDH2, ZEB1, and VIM) in HMLE or HMLE+β2 inhibitor treated with or without neutralizing anti-TGF-β1 antibody. GAPDH was used 
as a reference gene. Data are shown as fold change relative to DMSO-treated HMLE. Error bars indicate SEM (n ≥ 3).
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in HMLE cells is the stabilization of the TGFR2 at the cell 
surface, thereby resulting in increased TGF-β1 signaling 
and induction of the EMT transcriptional program.
DISCUSSION
It is established that EMT can generate cells with 
CSC properties, but the molecular mechanisms that induce 
EMT have not been fully elucidated. In the present study, 
we found that epithelial cells decrease their proteasome 
activity during EMT and that proteasome inhibitors 
can induce EMT. Mechanistically, we show that one 
consequence of downregulated proteasome activity may 
be increased TGF-β1 signaling, a potent inducer of EMT. 
However, it remains possible that a decrease in proteasome 
activity may enhance the stability of other EMT-promoting 
factors. For example, glycogen synthase kinase-3β 
(GSK3β)-mediated phosphorylation of SNAI1 has been 
shown to facilitate its nuclear export and degradation [9, 
33], while SNAI2 can undergo proteasome-dependent 
degradation mediated by the p53-MDM2 complex [9, 34]. 
In addition, phosphorylation of TWIST1 by the MAPK 
p38-JNK-ERK complex protects it from degradation [9, 
35]. Thus, downregulation of proteasome activity may 
lead to the induction of the EMT program through effects 
mediated by other pathways in addition to enhanced 
TGF-β1 signaling.
In support of the potential clinical relevance of our 
observations, we show that proteasome subunit mRNA 
expression in human tumor samples correlates with disease 
progression (Figure 4A, 4B). These results are consistent 
with the finding that low expression of 19S proteasome 
subunit PSMD1 correlates with decreased probability of 
overall survival in a cohort of 82 head and neck squamous 
cell carcinoma patients [11]. Conversely, high expression 
of proteasome subunits PSMB7 [36] and PSMB4 [37] 
has been shown to be associated with decreased breast 
cancer patient survival and poor prognosis, respectively. 
The extent to which the expression of PSMD1, PSMB4, 
and PSMB7 affect proteasome activity remains poorly 
understood, and may provide a possible explanation for 
these contrasting observations. To our knowledge, ours 
is the first study that suggests a correlation between 
decreased expression of the catalytic proteasome subunits 
- PSMB2 and PSMB5 - and reduced survival of breast 
cancer patients.
Finally, our findings are intriguing in light of the 
clinical use of proteasome inhibitors for the treatment 
of cancer. While many patients with hematopoietic 
malignancies respond to the proteasome inhibitor 
bortezomib, clinical trials investigating the use of 
proteasome inhibitors for solid tumors have thus far 
been disappointing [38-40]. Our data suggest a possible 
molecular mechanism for this observed effect - that 
pharmacologic inhibition of the proteasome may result 
in induction of EMT and acquisition of certain attributes 
of CSCs. Paradoxically, our results also suggest 
the possibility that pharmacologic inhibition of the 
proteasome may not only induce EMT in breast cancer 
cells, but may also endow them with an enhanced capacity 
to survive against the stimuli that led to their induction in 
the first place (Figure 2E). Taken together, these results 
suggest caution in the use of proteasome inhibitors in 
tumor subtypes that follow the CSC paradigm and raise 
the possibility that the use of agents that activate the 
proteasome, such as inhibitors of the deubiquitinase 
USP14 [41], might instead be an effective therapeutic 
strategy in such cancers.
MATERIALS AND METHODS
Mice
All animal work was approved by the Institutional 
Animal Care and Use Guidelines of the University of 
California, San Diego. All mice were housed in specific 
pathogen-free conditions prior to use. 
Cell culture
Immortalized human mammary epithelial cells 
(HMLE), HMLE-Snail, HMLE-Twist, HMLE-Ras 
(HMLER), and HMLER-Twist were maintained as 
previously described [32, 42]. MCF10A cells were 
obtained from Dr. Karra Muller (UCSD) and cultured in 
Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture 
F-12 supplemented with 5% FBS, 20ng/ml EGF, 0.5mg/
ml Hydrocortisone, 10ug/ml Insulin, 100ng/ml Cholera 
toxin, and Penicillin-Streptomycin. TGF-β1 treatment 
was performed as previously reported [6]. Epoxomicin 
(Enzo Life Sciences) was used at 12.5µM. Anti-TGF-β1 
neutralizing antibodies (Bio X Cell) were used at a 
concentration of 10μg/mL.
Activity-based proteasome probes and proteasome 
inhibitors
Subunit-selective activity-based proteasome probes, 
MVB003 (pan-reactive), LW124 (β1 subunit-reactive), 
and PR592 (β5 subunit-reactive) and subunit-selective 
proteasome inhibitors, NC001 (β1 subunit-reactive), 
LU102 (β2 subunit-reactive), and LU005 (β5 subunit-
reactive) were reconstituted in DMSO and have been 
previously described (Supplementary Figure S1) [24-
27]. In brief, the proteasome inhibitors were designed for 
selective and irreversible binding to proteolytically active 
proteasome subunits. Activity-based probes (ABPs) are 
similar to the proteasome inhibitors, except that they carry 
a fluorescent group that allows visualization of proteins 
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bands by SDS-PAGE. For selective proteasome inhibition, 
cells were cultured in media containing 5% fetal bovine 
serum in the presence of 5μM β1 inhibitor, 5μM β2 
inhibitor, or 0.5μM β5 inhibitor up to 14 days. For analysis 
of short-term effects of proteasome inhibition on TGF-β 
signaling, cells were treated for 24 hours.
In-gel proteasome activity assay
Cells were mechanically disrupted in 50mM Tris, 
pH7.4. 100 μg of total protein was incubated with 0.5μM 
pan-reactive probe (MVB003), 0.5μM β1 probe (LW124), 
or 1μM β5 probe (PR592) for 3 hrs at 37°C in 50mM Tris, 
pH7.4 buffer supplemented with 5mM MgCl2, 250mM 
sucrose, 1mM DTT, and 2mM ATP. After the reaction, 
samples were resolved on Novex 4-20% Tris-Glycine 
Mini Protein Gels (Life Technologies) and the fluorescent 
signals were detected using FluorChem Q (ProteinSimple). 
Densitometry was used to quantify the signals. Because 
the activity-based probes bind stoichiometrically to 
selective proteasome subunits, the fluorescent signal 
measured is linearly proportional to the activity of the 
specific β subunit. Beta2 subunit activity was determined 
by using the pan-reactive probe (MVB003) and analyzing 
the the fluorescent band at ~23 kDa.
Immunoblotting and antibodies
Cells were lysed on ice in buffer containing 50mM 
HEPES, pH7.4, 80mM NaCl, 5mM MgCl2, 10mM EDTA, 
5mM sodium pyrophosphate*10H2O, 1% TritonX-100, 
and Protease Inhibitor Cocktail (Sigma-Aldrich). 30 μg 
of total protein from each sample was resolved on Novex 
4-20% Tris-Glycine Mini Protein Gels and transferred 
onto nitrocellulose membranes. The blots were probed 
with the appropriate antibodies: anti-ubiquitin (Cell 
Signaling Technology), anti-β-actin (Sigma-Aldrich), anti-
20S/β1 subunit (Santa Cruz Biotechnology, Inc.), anti-20S/
β2 subunit (Santa Cruz Biotechnology, Inc.), anti-20S/β5 
subunit (Santa Cruz Biotechnology, Inc.), anti-E-cadherin 
(BD Biosciences), anti-fibronectin (BD Biosciences), 
anti-vimentin (Cell Signaling Technology), anti-phospho-
Smad2 (Ser465/467) (Cell Signaling Technology), or 
anti-Smad2/3 (Cell Signaling Technology). Signals were 
detected using Odyssey infrared imaging system (LI-Cor 
Biosciences). 
Flow cytometry analysis and cell sorting
Suspensions of HMLE or MCF10A cells were 
stained with anti-CD44 antibody (Biolegend), anti-CD24 
antibody (Biolegend), 7-AAD (eBioscience), Annexin-V 
(eBioscience), or anti-TGFR2 antibody (R&D Systems) 
and analyzed by flow cytometry on a BD Accuri C6 
(BD Biosciences). Data were analyzed using FlowJo 
software. Cell sorting was done using at FACSAria (BD 
Biosciences) at the UCSD Human Embryonic Stem Cell 
Core Facility. 
Mammosphere culture
Mammosphere culture was performed as previously 
described [6, 43], except that 2000 single cells for the 
primary culture and 1000 dissociated cells for the serial 
passages were plated per well of a 24-well plate. For serial 
passage studies, mammospheres were first dissociated 
into single cells and then plated in mammosphere culture 
conditions. This process was repeated three times.
Tumorigenesis assay
Five million HMLER cells per group (control 
HMLER, HMLER-Twist, or HMLER+β2 inhibitor) were 
injected subcutaneously into homozygous nude mice. 
A total of 12 animals were used for each condition. The 
tumor incidence and the tumor size were monitored for 
two months following injection.
Confocal microscopy
Following growth on coverslips for 2 days and 
treatment with DMSO, β2 inhibitor, β5 inhibitor or 
TGF-β1 with or without anti-TGF-β1 antibodies, 
immunofluorescence of HMLEs and MCF10A was 
performed as previously described [44] using anti-
E-cadherin (BD Biosciences), anti-fibronectin (BD 
Biosciences), anti-vimentin (Cell Signaling Technology), 
or anti-Smad4 (B-8) (Santa Cruz Biotechnology) followed 
by anti-rabbit Alexa Fluor 555 or anti-mouse Alexa 
Fluor 488 (Life Technologies) antibodies. DAPI (Life 
Technologies) was used to detect DNA. Acquisition of 
image stacks was performed as previously described 
[44] using a FV1000 laser scanning confocal microscope 
(Olympus). Fluorescence within the nucleus or cytoplasm 
was quantified using ImageJ software.
Microarray analysis
Total RNA was isolated from HMLE cells 
using TRIzol (Life Technologies). RNA was extracted 
from TRIzol using chloroform and precipitated with 
isopropanol. cDNA was then synthesized using the 
High Capacity cDNA Reverse Transcription Kit (Life 
Technologies) and hybridized to HumanHT-12_v4 arrays 
according to standard protocols (Illumina). Raw data were 
quantile normalized.
Differential expression analysis of Affymetrix array 
data was conducted using the Array Studio analysis suite 
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(Omicsoft, Inc). Datasets were quantile-normalized at the 
gene-level and log-transformed before computing one-
way ANOVA statistics between treatment and control 
group samples. Principal component analysis was used to 
detect possible outliers and batch effects across samples. 
Differentially expressed gene signatures representing 
1-5% of the coding transcriptomes were generated using a 
FDR < 0.0001. Functional enrichment of the differentially 
expressed genes was performed using GSEA, as 
previously described [45, 46], and IPA (Ingenuity). Genes 
significantly upregulated and downregulated in HMLE-
Snail were used as the enrichment set. Other enrichment 
sets used were taken from the Molecular Signatures 
Database [45]. Enrichment set names are included in 
Supplementary Table 1.
Real-time quantitative PCR
Total RNA was extracted using TRIzol (Life 
Technologies) and was reverse-transcribed with 
MultiScribe Reverse Transcriptase (Life Technologies). 
The resulting cDNAs were used for qPCR using 
SsoAdvance SYBR Green Supermix (Bio-Rad) in 
triplicate. PCR and data collection were performed on 
CFX96 Touch Real-Time PCR Detection System (Bio-
Rad). All the values were normalized to an internal control 
GAPDH. Relative expression for each target gene was 
compared to that of HMLE or MCF10A, and the data 
were presented as relative fold change. See Supplementary 
Information for primer sequences.
Kaplan-Meier analysis
Kaplan-Meier survival curves were generated from 
The Cancer Genome Atlas Breast Invasive Carcinoma 
Illumina HiSeq gene expression dataset (n = 1215). 
Patients were stratified based on the combined expression 
of proteasome catalytic subunit genes PSMB2 and 
PSMB5. High and low expression is defined as the top 
20% (n = 245 of 1215) and bottom 22% (n = 277 of 1215) 
of the patient distribution, respectively. Expression and 
overall survival data were downloaded from the UCSC 
Cancer Genomics Browser (https://genome-cancer.ucsc.
edu/). Prism (GraphPad) was used to test the statistical 
significance between the  overall survival curves using the 
Log-rank (Mantel-Cox) Test.
Oncomine analysis
Oncomine Platform (v4.5, Life Technologies) was 
used to analyze single gene expression in normal versus 
tumor samples, using the Finak Breast dataset [47].
Statistics
Statistical analyses were performed with a unpaired 
t test using GraphPad Software. The resulting statistics are 
indicated in each figure as follows: ns = Not significant (P 
> 0.05), Significant: * = (P ≤ 0.05), ** = (P ≤ 0.01), *** = 
(P ≤ 0.001), **** = (P ≤ 0.0001).
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